PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: biology

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION …

PRODUCT MONOGRAPH Master TemplateTemplate date: September 2020 FORXIGA (dapagliflozin propanediol monohydrate)Page 1 of 75 COPYRIGHT 2014-2021 ASTRAZENECA CANADA INCPRODUCT MONOGRAPHINCLUDING PATIENT MEDICATION INFORMATIONFORXIGA Dapagliflozin propanediol monohydrateTablets, 5 mg and 10 mg, OralATC Code: A10BK01 Sodium-glucose co-transporter 2 ( sglt2 ) inhibitorsAstraZeneca Canada Middlegate RoadMississauga, OntarioL4Y of Initial Authorization:Dec 10, 2014 Date of Revision:Aug 06, 2021 Submission Control Number: 248367 FORXIGA is a registered trademark of AstraZeneca AB, used under license byAstraZeneca Canada MONOGRAPH Master TemplateTemplate date: September 2020 FORXIGA (dapagliflozin propanediol monohydrate)Page 2 of 75 COPYRIGHT 2014-2021 ASTRAZENECA CANADA INCRECENT MAJOR LABEL CHANGES1 INDICATIONS08/20212 CONTRAINDICATIONS08/20214 DOSAGE AND ADMINISTRATION, Dosing Considerations08/20214 DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustm

Clinical trial and post-market cases of diabetic ketoacidosis (DKA), a serious life-threatening ... FORXIGA and other sodium-glucose co-transporter 2 (SGLT2) inhibitors. A number of these cases have been atypical with blood glucose values below 13.9 mmol/L (250 mg/dL). ... In patients with chronic kidney disease, the recommended dose of FORXIGA ...

Fullscreen Download

Tags:

  Disease, Kidney, Kidney disease, Diabetic, Inhibitors, Sglt2

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION …

Documents from same domain

PRODUCT MONOGRAPH INCLUDING PATIENT …

www.astrazeneca.ca

INCLUDING PATIENT MEDICATION INFORMATION LYNPARZA ... including long-term survival follow-up, and the majority of events had a fataloutcome. All patients had potential contributing factors for the development of MDS/AML, having received

  Information, Patients, Medication, Including, Including patient medication information, Including patient

INCLUDING PATIENT MEDICATION INFORMATION

www.astrazeneca.ca

other information relevant to the use of the drug. Patients should be advised to contact their healthcare provider immediately to report any new chest pain or discomfort, changes in

  Information, Patients, Medication, Including, Including patient medication information

Forxiga Consumer Information - AstraZeneca

www.astrazeneca.ca

Product Monograph Master Template Template date: September 2020 FORXIGA (dapagliflozin propanediol monohydrate) Page 3 of 8 COPYRIGHT 2014-2021 ASTRAZENECA CANADA INC FORXIGA and when to start taking it again. have a sudden reduction in your insulin dose have a history of DKA. • are older than 65 years of age

  Information, Product, Monographs, Consumer, Product monograph, Consumer information

PRODUCT MONOGRAPH SYMBICORT …

www.astrazeneca.ca

indicated for the maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema, in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate. SYMBICORTTURBUHALER is NOT indicated for the relief of acute bronchospasm in COPD patients.

  Product, Monographs, Including, Product monograph

Related documents

Fact sheet Type 2 diabetes - Centre for Pharmacy ...

www.cppe.ac.uk

can be tested for as the kidneys begin to leak proteins which pass into the urine.14 Kidney disease accounts for 11 percent of deaths in people with T2DM, and about 75 percent of those with diabetes develop chronic kidney disease (CKD).12 For more information on nephropathy, visit the Diabetes UK page Diabetic nephropathy (Kidney disease).

  Disease, Kidney, Kidney disease, Diabetic

<insert self-management goal> Quick Reference Guide

guidelines.diabetes.ca

SGLT2 inhibitors cana & empa: Superiority with type 2 diabetes with clinical CVD Rare ˜ ˜˜ ˜ to ˜ ˜ ˜ Genital infections, UTI, hypotension, dose-related changes in LDL-C. Caution with renal dysfunction, loop diuretics, in the elderly. Dapaglifl ozin not to be used if bladder cancer. Rare diabetic ketoacido- sis (may occur with no ...

  Diabetic, Inhibitors, Sglt2, Sglt2 inhibitors

HIGHLIGHTS OF PRESCRIBING INFORMATION ...

www.accessdata.fda.gov

marketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors, including JARDIANCE. Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m), elderly patients, or patients on loop diuretics may be at increased risk for

  Kidney, Inhibitors, Sglt2, Sglt2 inhibitors

Related search queries

Kidney disease, Diabetic, SGLT2 inhibitors, Kidney